TABLE 3:
ANCILARY TRIALS AND STUDIES LINKED TO PREDICT
| Clinical Trial or Research Study | Sample/cohort | Sponsor | Ref |
|---|---|---|---|
| Healthcare Associated Links in Transmission of NTM in Patients with CF (NCT04024423, NCT05686837) | NTM isolates | CFF (GROSS19Q0) (GROSSY5) |
(9, 13, 32) |
| Protocol for Bacteriophage Treatment of Mycobacteria abscessus through An Investigational New Drug Application | NTM isolates, blood, urine, sputum, clinical data in a participant with NTM-PD | FDA (IND 26902) |
(33, 34) |
| A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are Colonized with Nontuberculous Mycobacteria (ABATE Trial)(NCT04294043) | NTM isolates, participants with indolent infection | FDA (R01FD-R-6848) CFF |
|
| Prospective Longitudinal Assessment of Culture-Independent Molecular Airway Markers of Nontuberculous Mycobacteria | Sputum, NTM isolates, clinical data | NIH (HL146228) |
(35, 36) |
| Improving NTM Disease Diagnosis Through Use of a Novel High-Resolution Chest CT Score | HRCT scans, clinical data | CFF (MARTIN22K0, MARTIN20Y5) |
|
| Prospective Evaluation of Markers of NTM and Host Response in Saliva | Saliva, clinical data | CFF (NICK21KO) |
(31) |
| Population Genomics of NTM in Cystic Fibrosis Care Centers, United States | NTM isolates, culture and clinical data | NIH (AI125726) CFF (NICK15R0) |
(4, 5, 37) |
| Prospective Algorithm for Treatment of NTM in Cystic Fibrosis (PATIENCE)(NCT02419989) | Participants with NTM-PD | CFF (NICK17K0) |
|
| PrOSpecTive STandardized Assessment of MycobacterioPhage (POSTSTAMP) Trial | Participants with treatment refractory NTM-PD | CFF (NICK23A0) |